Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications

References

• Winkelstein W Jr. Not just a country doctor: Edward Jenner, scientist. Epidemiol. Rev.14, 1–15 (1992).
   PubMed Web of Science ®Google Scholar
• Willis NJ. Edward Jenner and the eradication of smallpox. Scott. Med. J.42(4), 118–121 (1997).
   PubMed Web of Science ®Google Scholar
• Jalava K, Hensel A, Szostak M, Resch S, Lubitz W. Bacterial ghosts as vaccine candidates for veterinary applications. J. Cont. Rel.85(1–3), 17–25 (2002).
   PubMed Web of Science ®Google Scholar
• Kaminski RW, Oaks EV. Inactivated and subunit vaccines to prevent shigellosis. Expert Rev. Vaccines8(12), 1693–1704 (2009).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine28(Suppl. 3), C25–C36 (2010).
   PubMed Web of Science ®Google Scholar
• Patel JR, Heldens JG. Immunoprophylaxis against important virus disease of horses, farm animals and birds. Vaccine27(12), 1797–1810 (2009).
   PubMedGoogle Scholar
• Silva AJ, Eko FO, Benitez JA. Exploiting cholera vaccines as a versatile antigen delivery platform. Biotechnol. Lett.30(4), 571–579 (2008).
   PubMed Web of Science ®Google Scholar
• Walker RI, Steele D, Aguado T. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine25(14), 2545–2566 (2007).
   PubMed Web of Science ®Google Scholar
• Zepp F. Principles of vaccine design-lessons from nature. Vaccine28(Suppl. 3), C14–C24 (2010).
   PubMed Web of Science ®Google Scholar
• Ito Y. A tumor-producing factor extracted by phenol from papillomatous tissue (Shope) of cottontail rabbits. Virology12, 596–601 (1960).
   PubMed Web of Science ®Google Scholar
• Liu MA, Wahren B, Karlsson Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum. Gene Ther.17(11), 1051–1061 (2006).
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science247(4949 Pt 1), 1465–1468 (1990).
   PubMed Web of Science ®Google Scholar
• Dhama K, Mahendran M, Gupta PK, Rai A. DNA vaccines and their applications in veterinary practice: current perspectives. Vet. Res. Commun.32(5), 341–356 (2008).
   PubMed Web of Science ®Google Scholar
• Babiuk S, Tsang C, van Drunen Littel-van den Hurk S, Babiuk LA, Griebel PJ. A single HBsAg DNA vaccination in combination with electroporation elicits long-term antibody responses in sheep. Bioelectrochemistry70(2), 269–274 (2007).
   PubMed Web of Science ®Google Scholar
• Oshop GL, Elankumaran S, Heckert RA. DNA vaccination in the avian. Vet. Immunol. Immunopathol.89(1–2), 1–12 (2002).
   PubMed Web of Science ®Google Scholar
• Dunham SP. The application of nucleic acid vaccines in veterinary medicine. Res. Vet. Sci.73(1), 9–16 (2002).
   PubMed Web of Science ®Google Scholar
• Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol.26(7), 373–380 (2005).
   PubMed Web of Science ®Google Scholar
• Nagaraju K. Immunological capabilities of skeletal muscle cells. Acta Physiol. Scand.171(3), 215–223 (2001).
   PubMedGoogle Scholar
• Paukner S, Kudela P, Kohl G, Schlapp T, Friedrichs S, Lubitz W. DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages. Mol. Ther.11(2), 215–223 (2005).
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization*. Ann. Rev. Immunol.18, 927–974 (2000).
   PubMed Web of Science ®Google Scholar
• Henriksen -Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Exp. Opin. Drug Deliv.8(4), 505–519 (2011).
   PubMedGoogle Scholar
• Arias JL, Clares B, Morales ME, Gallardo V, Ruiz MA. Lipid-based drug delivery systems for cancer treatment. Curr. Drug Targets12(8), 1151–1165 (2011).
   PubMed Web of Science ®Google Scholar
• Poirier VJ, Thamm DH, Kurzman ID et al. Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J. Vet. Intern. Med.16(6), 726–731 (2002).
   PubMed Web of Science ®Google Scholar
• Marr AK, Kurzman ID, Vail DM. Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs. Am. J. Vet. Res.65(11), 1474–1478 (2004).
   PubMed Web of Science ®Google Scholar
• U’Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J. Vet. Intern. Med.21(1), 113–120 (2007).
   PubMedGoogle Scholar
• Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J. Cont. Rel.76(1–2), 59–71 (2001).
   PubMed Web of Science ®Google Scholar
• Zaks K, Jordan M, Guth A et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol.176(12), 7335–7345 (2006).
   PubMed Web of Science ®Google Scholar
• Tanaka T, Legat A, Adam E et al. DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. Eur. J. Immunol.38(5), 1351–1357 (2008).
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Morel S, Lockman L et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol.183(10), 6186–6197 (2009).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol.10(11), 787–796 (2010).
   PubMed Web of Science ®Google Scholar
• Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S et al. Combination adjuvants: the next generation of adjuvants? Expert Rev. Vaccines10(1), 95–107 (2011).
   PubMed Web of Science ®Google Scholar
• Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv. Immunol.73, 329–368 (1999).
   PubMed Web of Science ®Google Scholar
• Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol.4(4), 249–258 (2004).
   PubMed Web of Science ®Google Scholar
• Krieg AM. CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol.20, 709–760 (2002).
   PubMed Web of Science ®Google Scholar
• US FDA. Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Rockville, MD, USA (1998).
   Google Scholar
• EMEA. Overview of Comments Received on Guideline on the Non-clinical Studies Required Prior to Clinical Use of Gene Therapy Medicinal Products. EMEA/CHMP/GTWP/65260/2008. European Medicines Agency, London, UK (2008).
   Google Scholar
• EMEA. Guideline on the Non-clinical Studies Required Prior to Clinical Use of Gene Therapy Medicinal Products. EMEA/CHMP/GTWP/125459/2006. European Medicines Agency, London, UK (2008).
   Google Scholar
• EMEA. Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer. CPMP/BWP/3088/99. European Medicines Agency, London, UK (2001).
   Google Scholar
• Calarota SA, Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol. Rev.199, 84–99 (2004).
   PubMed Web of Science ®Google Scholar
• Scheerlinck JY. Genetic adjuvants for DNA vaccines. Vaccine19(17–19), 2647–2656 (2001).
   PubMed Web of Science ®Google Scholar
• Garver KA, LaPatra SE, Kurath G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Dis. Aquat. Organ.64(1), 13–22 (2005).
   PubMed Web of Science ®Google Scholar
• Davidson AH, Traub-Dargatz JL, Rodeheaver RM et al. Immunologic responses to West Nile virus in vaccinated and clinically affected horses. J. Am. Vet. Med. Assoc.226(2), 240–245 (2005).
   PubMed Web of Science ®Google Scholar
• Davis EG, Zhang Y, Tuttle J, Hankins K, Wilkerson M. Investigation of antigen specific lymphocyte responses in healthy horses vaccinated with an inactivated West Nile virus vaccine. Vet. Immunol. Immunopathol.126(3–4), 293–301 (2008).
   PubMedGoogle Scholar
• Bergman PJ, Camps-Palau MA, McKnight JA et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center. Vaccine24(21), 4582–4585 (2006).
   PubMed Web of Science ®Google Scholar
• Thacker EL, Holtkamp DJ, Khan AS, Brown PA, Draghia-Akli R. Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection. J. Anim. Sci.84(3), 733–742 (2006).
   PubMed Web of Science ®Google Scholar
• Liu MA. Immunologic basis of vaccine vectors. Immunity33(4), 504–515 (2010).
   PubMed Web of Science ®Google Scholar
• Tabrizi CA, Walcher P, Mayr UB et al. Bacterial ghosts – biological particles as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol.15(6), 530–537 (2004).
   PubMed Web of Science ®Google Scholar
• Lubitz W, Witte A, Eko FO et al. Extended recombinant bacterial ghost system. J. Biotechnol.73(2–3), 261–273 (1999).
   PubMed Web of Science ®Google Scholar
• Szostak MP, Hensel A, Eko FO et al. Bacterial ghosts: non-living candidate vaccines. J. Biotechnol.44(1–3), 161–170 (1996).
   PubMed Web of Science ®Google Scholar
• Szostak M, Lubitz W. Recombinant bacterial ghosts as multivaccine vehicles. In: Vaccines 91: Modern Approaches to New Vaccines Including Prevention of AIDS. Chanock R (Ed.). Cold Spring Harbor Laboratory Press, NY, USA 409–414 (1991).
   Google Scholar
• Lubitz P, Mayr UB, Lubitz W. Applications of bacterial ghosts in biomedicine. Adv. Exp. Med. Biol.655, 159–170 (2009).
   PubMed Web of Science ®Google Scholar
• Mayr B, Koller VJ, Lubitz P, Lubitz W. Bacterial Ghosts as Vaccine and Drug Delivery Platforms. Sleator R, Hill C (Eds). Landes Bioscience, Austin, TX, USA (2008).
   Google Scholar
• Witte A, Wanner G, Blasi U, Halfmann G, Szostak M, Lubitz W. Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E. J. Bacteriol.172(7), 4109–4114 (1990).
   PubMed Web of Science ®Google Scholar
• Huter V, Szostak MP, Gampfer J et al. Bacterial ghosts as drug carrier and targeting vehicles. J. Cont. Rel.61(1–2), 51–63 (1999).
   PubMed Web of Science ®Google Scholar
• Paukner S, Kohl G, Jalava K, Lubitz W. Sealed bacterial ghosts – novel targeting vehicles for advanced drug delivery of water-soluble substances. J. Drug Target11(3), 151–161 (2003).
   PubMed Web of Science ®Google Scholar
• Witte A, Wanner G, Sulzner M, Lubitz W. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch. Microbiol.157(4), 381–388 (1992).
   PubMed Web of Science ®Google Scholar
• Riedmann EM, Kyd JM, Cripps AW, Lubitz W. Bacterial ghosts as adjuvant particles. Expert Rev. Vaccines6(2), 241–253 (2007).
   PubMed Web of Science ®Google Scholar
• Langemann T, Koller VJ, Muhammad A, Kudela P, Mayr UB, Lubitz W. The bacterial ghost platform system: production and applications. Bioeng. Bugs1(5), 326–336 (2010).
   PubMedGoogle Scholar
• Ebensen T, Paukner S, Link C et al. Bacterial ghosts are an efficient delivery system for DNA vaccines. J. Immunol.172(11), 6858–6865 (2004).
   PubMed Web of Science ®Google Scholar
• Eko FO, Lubitz W, McMillan L et al. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine21(15), 1694–1703 (2003).
   PubMed Web of Science ®Google Scholar
• Eko FO, Mayr UB, Attridge SR, Lubitz W. Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. J. Biotechnol.83(1–2), 115–123 (2000).
   PubMed Web of Science ®Google Scholar
• Eko FO, Schukovskaya T, Lotzmanova EY et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine21(25–26), 3663–3674 (2003).
   PubMed Web of Science ®Google Scholar
• Ekong EE, Okenu DN, Mania-Pramanik J et al. A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin. FEMS Immunol. Med. Microbiol.55(2), 280–291 (2009).
   PubMed Web of Science ®Google Scholar
• Hensel A, Huter V, Katinger A et al. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine18(26), 2945–2955 (2000).
   PubMed Web of Science ®Google Scholar
• Huter V, Hensel A, Brand E, Lubitz W. Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J. Biotechnol.83(1–2), 161–172 (2000).
   PubMed Web of Science ®Google Scholar
• Jechlinger W, Haller C, Resch S, Hofmann A, Szostak MP, Lubitz W. Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts. Vaccine23(27), 3609–3617 (2005).
   PubMed Web of Science ®Google Scholar
• Katinger A, Lubitz W, Szostak MP et al. Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses. J. Biotechnol.73(2–3), 251–260 (1999).
   PubMed Web of Science ®Google Scholar
• Marchart J, Rehagen M, Dropmann G et al. Protective immunity against pasteurellosis in cattle, induced by Pasteurella haemolytica ghosts. Vaccine21(13–14), 1415–1422 (2003).
   PubMed Web of Science ®Google Scholar
• Mayr UB, Haller C, Haidinger W et al. Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge. Infect. Immun.73(8), 4810–4817 (2005).
   PubMed Web of Science ®Google Scholar
• Walcher P, Cui X, Arrow JA et al. Bacterial ghosts as a delivery system for zona pellucida-2 fertility control vaccines for brushtail possums (Trichosurus vulpecula). Vaccine26(52), 6832–6838 (2008).
   PubMed Web of Science ®Google Scholar
• Eko FO, Hensel A, Bunka S, Lubitz W. Immunogenicity of Vibrio cholerae ghosts following intraperitoneal immunization of mice. Vaccine12(14), 1330–1334 (1994).
   PubMed Web of Science ®Google Scholar
• Eko FO, Okenu DN, Singh UP, He Q, Black C, Igietseme JU. Evaluation of a broadly protective Chlamydia–cholera combination vaccine candidate. Vaccine29(21), 3802–3810 (2011).
   PubMedGoogle Scholar
• Jechlinger W, Szostak MP, Witte A, Lubitz W. Altered temperature induction sensitivity of the lambda pR/cI857 system for controlled gene E expression in Escherichia coli. FEMS Microbiol. Lett.173(2), 347–352 (1999).
   PubMed Web of Science ®Google Scholar
• Witte A, Blasi U, Halfmann G, Szostak M, Wanner G, Lubitz W. Phi X174 protein E-mediated lysis of Escherichia coli. Biochimie72(2–3), 191–200 (1990).
   PubMed Web of Science ®Google Scholar
• Witte A, Lubitz W. Biochemical characterization of phi X174-protein-E-mediated lysis of Escherichia coli.Eur. J. Biochem.180(2), 393–398 (1989).
   PubMedGoogle Scholar
• Blasi U, Henrich B, Lubitz W. Lysis of Escherichia coli by cloned phi X174 gene E depends on its expression. J. Gen. Microbiol.131(5), 1107–1114 (1985).
   PubMedGoogle Scholar
• Henrich B, Lubitz W, Plapp R. Lysis of Escherichia coli by induction of cloned phi X174 genes. Mol. Gen. Genet.185(3), 493–497 (1982).
   PubMedGoogle Scholar
• Mayr UB, Walcher P, Azimpour C, Riedmann E, Haller C, Lubitz W. Bacterial ghosts as antigen delivery vehicles. Adv. Drug Deliv. Rev.57(9), 1381–1391 (2005).
   PubMed Web of Science ®Google Scholar
• Jalava K, Eko FO, Riedmann E, Lubitz W. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev. Vaccines2(1), 45–51 (2003).
   PubMedGoogle Scholar
• Lubitz W, Pugsley AP. Changes in host cell phospholipid composition of øX174 gene E product. FEMS Microbiol. Lett.30(1–2), 171–175 (1985).
   Web of Science ®Google Scholar
• Witte A, Lubitz W, Bakker EP. Proton-motive-force-dependent step in the pathway to lysis of Escherichia coli induced by bacteriophage phi X174 gene E product. J. Bacteriol.169(4), 1750–1752 (1987).
   PubMed Web of Science ®Google Scholar
• Lubitz W, Halfmann G, Plapp R. Lysis of Escherichia coli after infection with phiX174 depends on the regulation of the cellular autolytic system. J. Gen. Microbiol.130(Pt 5), 1079–1087 (1984).
   PubMedGoogle Scholar
• Schon P, Schrot G, Wanner G, Lubitz W, Witte A. Two-stage model for integration of the lysis protein E of phi X174 into the cell envelope of Escherichia coli. FEMS Microbiol. Rev.17(1–2), 207–212 (1995).
   PubMed Web of Science ®Google Scholar
• Witte A, Schrot G, Schon P, Lubitz W. Proline 21, a residue within the alpha-helical domain of phiX174 lysis protein E, is required for its function in Escherichia coli. Mol. Microbiol.26(2), 337–346 (1997).
   PubMed Web of Science ®Google Scholar
• Ronchel MC, Molina L, Witte A et al. Characterization of cell lysis in Pseudomonas putida induced upon expression of heterologous killing genes. Appl. Environ. Microbiol.64(12), 4904–4911 (1998).
   PubMed Web of Science ®Google Scholar
• Kloos DU, Stratz M, Guttler A, Steffan RJ, Timmis KN. Inducible cell lysis system for the study of natural transformation and environmental fate of DNA released by cell death. J. Bacteriol.176(23), 7352–7361 (1994).
   PubMed Web of Science ®Google Scholar
• Jechlinger W, Szostak MP, Lubitz W. Cold-sensitive E-lysis systems. Gene218(1–2), 1–7 (1998).
   PubMed Web of Science ®Google Scholar
• Kwon SR, Nam YK, Kim SK, Kim KH. Protection of tilapia (Oreochromis mosambicus) from edwardsiellosis by vaccination with Edwardsiella tarda ghosts. Fish Shellfish Immunol.20(4), 621–626 (2006).
   PubMed Web of Science ®Google Scholar
• Perrin P, Morgeaux S. Inactivation of DNA by β-propiolactone. Biologicals23(3), 207–211 (1995).
   PubMed Web of Science ®Google Scholar
• Haidinger W, Mayr UB, Szostak MP, Resch S, Lubitz W. Escherichia coli ghost production by expression of lysis gene E and Staphylococcal nuclease. Appl. Environ. Microbiol.69(10), 6106–6113 (2003).
   PubMed Web of Science ®Google Scholar
• Langemann T. Process development for industrial scale bacterial ghost production. University of Vienna, Vienna, Austria (2011).
   Google Scholar
• Ifere GO, He Q, Igietseme JU et al. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine. J. Microbiol. Immunol. Infect.40(3), 188–200 (2007).
   PubMedGoogle Scholar
• Macmillan L, Ifere GO, He Q et al. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol. Med. Microbiol.49(1), 46–55 (2007).
   PubMedGoogle Scholar
• Ramey K, Eko FO, Thompson WE, Armah H, Igietseme JU, Stiles JK. Immunolocalization and challenge studies using a recombinant Vibrio cholerae ghost expressing Trypanosoma brucei Ca(2+) ATPase (TBCA2) antigen. Am. J. Trop. Med. Hyg.81(3), 407–415 (2009).
   PubMedGoogle Scholar
• Hobom G, Arnold N, Ruppert A. OmpA fusion proteins for presentation of foreign antigens on the bacterial outer membrane. Dev. Biol. Stand.84, 255–262 (1995).
   PubMedGoogle Scholar
• Jechlinger W, Haidinger W, Paukner S et al. Bacterial ghosts as carrier and targeting systems for antigen delivery. In: Vaccine Delivery Strategies. Dietrich G, Goebel W (Eds). Horizon Scientific Press, Wymondham, Norfolk, UK, 163–184 (2002).
   Google Scholar
• Schulman H, Kennedy EP. Localization of membrane-derived oligosaccharides in the outer envelope of Escherichia coli and their occurrence in other Gram-negative bacteria. J. Bacteriol.137(1), 686–688 (1979).
   PubMedGoogle Scholar
• Lubitz W. Bacterial ghosts as carrier and targeting systems. Exp. Opin. Biol. Ther.1(5), 765–771 (2001).
   PubMed Web of Science ®Google Scholar
• Riedmann EM, Kyd JM, Smith AM et al. Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts – a delivery system for the nontypeable Haemophilus influenzae antigen Omp26. FEMS Immunol. Med. Microbiol.37(2–3), 185–192 (2003).
   PubMed Web of Science ®Google Scholar
• Walcher P, Mayr UB, Azimpour-Tabrizi C et al. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. Expert Rev. Vaccines3(6), 681–691 (2004).
   PubMedGoogle Scholar
• Kuen B, Sleytr UB, Lubitz W. Sequence analysis of the sbsA gene encoding the 130-kDa surface-layer protein of Bacillus stearothermophilus strain PV72. Gene145(1), 115–120 (1994).
   PubMed Web of Science ®Google Scholar
• Riedmann EM, Lubitz W, McGrath J, Kyd JM, Cripps AW. Effectiveness of engineering the nontypeable Haemophilus influenzae antigen Omp26 as an S-layer fusion in bacterial ghosts as a mucosal vaccine delivery. Hum. Vaccin.7(Suppl.), 99–107 (2011).
   PubMedGoogle Scholar
• Cui X, Duckworth JA, Lubitz P et al. Humoral immune responses in brushtail possums (Trichosurus vulpecula) induced by bacterial ghosts expressing possum zona pellucida 3 protein. Vaccine28(26), 4268–4274 (2010).
   PubMed Web of Science ®Google Scholar
• Mayrhofer P, Tabrizi CA, Walcher P, Haidinger W, Jechlinger W, Lubitz W. Immobilization of plasmid DNA in bacterial ghosts. J. Control. Release102(3), 725–735 (2005).
   PubMed Web of Science ®Google Scholar
• Jechlinger W, Azimpour Tabrizi C, Lubitz W, Mayrhofer P. Minicircle DNA immobilized in bacterial ghosts: in vivo production of safe non-viral DNA delivery vehicles. J. Mol. Microbiol. Biotechnol.8(4), 222–231 (2004).
   PubMed Web of Science ®Google Scholar
• Kudela P, Paukner S, Mayr UB et al. Effective gene transfer to melanoma cells using bacterial ghosts. Cancer Lett.262(1), 54–63 (2008).
   PubMed Web of Science ®Google Scholar
• Kudela P, Paukner S, Mayr UB et al. Bacterial ghosts as novel efficient targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells. J. Immunother.28(2), 136–143 (2005).
   PubMed Web of Science ®Google Scholar
• Chen ZY, He CY, Kay MA. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum. Gene Ther.16(1), 126–131 (2005).
   PubMed Web of Science ®Google Scholar
• Paukner S, Kohl G, Lubitz W. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J. Cont. Rel.94(1), 63–74 (2004).
   PubMed Web of Science ®Google Scholar
• Furst-Ladani S, Redl H, Haslberger A et al. Bacterial cell envelopes (ghosts) but not S-layers activate human endothelial cells (HUVECs) through sCD14 and LBP mechanism. Vaccine18(5–6), 440–448 (1999).
   PubMed Web of Science ®Google Scholar
• Kudela P, Koller VJ, Mayr UB, Nepp J, Lubitz W, Barisani-Asenbauer T. Bacterial ghosts as antigen and drug delivery system for ocular surface diseases: effective internalization of bacterial ghosts by human conjunctival epithelial cells. J. Biotechnol.153(3–4), 167–175 (2011).
   PubMed Web of Science ®Google Scholar
• Paukner S, Stiedl T, Kudela P, Bizik J, Al Laham F, Lubitz W. Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Exp. Opin. Drug Deliv.3(1), 11–22 (2006).
   PubMedGoogle Scholar
• Felnerova D, Kudela P, Bizik J et al. T cell-specific immune response induced by bacterial ghosts. Med. Sci. Monit.10(10), BR362–BR370 (2004).
   PubMed Web of Science ®Google Scholar
• Hensel A, van Leengoed LA, Szostak M et al. Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection model. J. Biotechnol.44(1–3), 171–181 (1996).
   PubMed Web of Science ®Google Scholar
• Guan L, Mu W, Champeimont J et al. Iron-regulated lysis of recombinant escherichia coli in host releases protective antigen and confers biological containment. Infect. Immun.79(7), 2608–2618 (2011).
   PubMedGoogle Scholar
• Panthel K, Jechlinger W, Matis A et al. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect. Immun.71(1), 109–116 (2003).
   PubMed Web of Science ®Google Scholar
• Eko FO, Ekong E, He Q, Black CM, Igietseme JU. Induction of immune memory by a multisubunit chlamydial vaccine. Vaccine29(7), 1472–1480 (2011).
   PubMedGoogle Scholar
• Talebkhan Y, Bababeik M, Esmaeili M et al.Helicobacter pylori bacterial ghost containing recombinant Omp18 as a putative vaccine. J. Microbiol. Methods82(3), 334–337 (2010).
   PubMedGoogle Scholar
• Eko FO, Talin BA, Lubitz W. Development of a Chlamydia trachomatis bacterial ghost vaccine to fight human blindness. Hum. Vaccin.4(3), 176–183 (2008).
   PubMed Web of Science ®Google Scholar
• Foxwell AR, Kyd JM, Cripps AW. Mucosal immunization against respiratory bacterial pathogens. Expert Rev. Vaccines2(4), 551–560 (2003).
   PubMedGoogle Scholar
• Baqar S, Bourgeois AL, Schultheiss PJ et al. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine13(1), 22–28 (1995).
   PubMed Web of Science ®Google Scholar
• Mader HJ, Szostak MP, Hensel A, Lubitz W, Haslberger AG. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine15(2), 195–202 (1997).
   PubMed Web of Science ®Google Scholar
• Mayr UB, Kudela P, Atrasheuskaya A, Bukin E, Ignatyev GM, Lubitz W. Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge. Microb. Biotechnol. doi:10.1111/j.1751-7915.2011.00316.x (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Marchart J, Dropmann G, Lechleitner S et al.Pasteurella multocida- and Pasteurella haemolytica-ghosts: new vaccine candidates. Vaccine21(25–26), 3988–3997 (2003).
   PubMed Web of Science ®Google Scholar
• Gudding R, Lillehaug A, Evensen O. Recent developments in fish vaccinology. Vet. Immunol. Immunopathol.72(1–2), 203–212 (1999).
   PubMed Web of Science ®Google Scholar
• Plumb JA. Edwardsiella septicaemias In: Fish Diseases and Disorders. Volume 3: Viral Bacterial and Fungal Disorders. Woo PTK, Bruno DW (Eds). CAB International, Wallingford, UK 479–521 (1999).
   Google Scholar
• Kwon SR, Nam YK, Kim SK, Kim DS, Kim KH. Generation of Edwardsiella tarda ghosts by bacteriophage PhiX174 lysis gene E.Aquaculture250(1–2), 16–21 (2005).
   Google Scholar
• Hart S, Wrathmell AB, Harris JE, Grayson TH. Gut immunology in fish: a review. Develop. Comparat. Immunol.12(3), 453–480 (1988).
   PubMed Web of Science ®Google Scholar
• Kwon SR, Lee EH, Nam YK, Kim SK, Kim KH. Efficacy of oral immunization with Edwardsiella tarda ghosts against edwardsiellosis in olive flounder (Paralichthys olivaceus). Aquaculture269(1–4), 84–88 (2007).
   Web of Science ®Google Scholar
• Quentel C, Vigneulle M. Antigen uptake and immune responses after oral vaccination. Dev. Biol. Stand.90, 69–78 (1997).
   PubMedGoogle Scholar
• Kwon SR, Kang YJ, Lee DJ et al. Generation of Vibrio anguillarum ghost by coexpression of PhiX 174 lysis E gene and staphylococcal nuclease A gene. Mol. Biotechnol.42(2), 154–159 (2009).
   PubMedGoogle Scholar
• Talwar GP, Vyas HK, Purswani S, Gupta JC. Gonadotropin-releasing hormone/human chorionic gonadotropin β based recombinant antibodies and vaccines. J. Rep. Immunol.83(1–2), 158–163 (2009).
   PubMed Web of Science ®Google Scholar
• Purswani S, Talwar GP. Development of a highly immunogenic recombinant candidate vaccine against human chorionic gonadotropin. Vaccine29(12), 2341–2348 (2011).
   PubMed Web of Science ®Google Scholar
• Lubitz W, Harkness RE, Ishiguro EE. Requirement for a functional host cell autolytic enzyme system for lysis of Escherichia coli by bacteriophage phi X174. J. Bacteriol.159(1), 385–387 (1984).
   PubMedGoogle Scholar
• Wadle D, Henrich B, Plapp R. Effect of mutations in genes fadR, fabB, fadE and envC of Escherichia coli on the action of the lysis gene of bacteriophage PhiX174. Curr. Microbiol.14, 5 (1986).
   Google Scholar
• Maratea D, Young K, Young R. Deletion and fusion analysis of the phage phi X174 lysis gene E. Gene40(1), 39–46 (1985).
   PubMed Web of Science ®Google Scholar
• Halfmann G. Einfluss zellulaerar mutationen auf die PhiX174 protein E-induzierte lyse von Escherichia coli. University of Munich, Munich, Germany (1989).
   Google Scholar
• Witte A, Brand E, Mayrhofer P, Narendja F, Lubitz W. Mutations in cell division proteins FtsZ and FtsA inhibit phiX174 protein-E-mediated lysis of Escherichia coli. Arch. Microbiol.170(4), 259–268 (1998).
   PubMed Web of Science ®Google Scholar
• Witte A. Untersuchungen zur Wirkung von PhiX174 Protein E sowie davon abgeleiteter chimaerer Protein auf den Zellwandkomplex von Escherichia coli. University of Munich, Munich, Germany (1990).
   Google Scholar
• Blasi U, Young R, Lubitz W. Evaluation of the interaction of phi X174 gene products E and K in E-mediated lysis of Escherichia coli. J. Virol.62(11), 4362–4364 (1988).
   PubMedGoogle Scholar
• Zheng Y, Struck DK, Bernhardt TG, Young R. Genetic analysis of MraY inhibition by the phiX174 protein E. Genetics180(3), 1459–1466 (2008).
   PubMedGoogle Scholar
• Abtin A, Kudela P, Mayr UB et al.Escherichia coli ghosts promote innate immune responses in human keratinocytes. Biochem. Biophys. Res. Commun.400(1), 78–82 (2010).
   PubMed Web of Science ®Google Scholar
• Eko FO, He Q, Brown T et al. A novel recombinant multisubunit vaccine against Chlamydia. J. Immunol.173(5), 3375–3382 (2004).
   PubMed Web of Science ®Google Scholar
• Wang X, Lu C. Mice orally vaccinated with Edwardsiella tarda ghosts are significantly protected against infection. Vaccine27(10), 1571–1578 (2009).
   PubMed Web of Science ®Google Scholar
• Chu W, Zhuang X, Lu C. Generation of Aeromonas hydrophila ghosts and their evaluation as oral vaccine candidates in Carassius auratus gibelio. Wei Sheng Wu Xue Bao48(2), 202–206 (2008).
   PubMedGoogle Scholar